Dr. Shadi AlKhayyat

Associate Professor of Medicine and oncology
Consultant medical oncology
King Abdulaziz University

17 : 55 – 18 : 05

23 June | 2023 Day 1

Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.

4th PSMMC ASCO Data Review Meeting (PADRM). This meeting will highlight the top most clinically relevant achievements of ASCO 2023 for different and commonest tumor types.